Related Experiment Video
Updated: May 17, 2025
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Impact of delaying PCV20 implementation in France's pediatric national immunization program: A population-based
Johnna Perdrizet1, Emmanuelle Blanc2, Jessica Y El Khoury2
1Pfizer Canada, Kirkland, Quebec, Canada.
Objectives:
We assessed the public health and economic impacts in France for infants below 1-year of delaying PCV20 (3 + 1) implementation compared to continuous use of PCV15 (2 + 1) and PCV13 (2 + 1).
Patients And Methods:
Population-based Markov model was adapted for French pediatric population. Outcomes included pneumococcal disease cases, deaths, and direct costs. Impact of a PCV20 two-year implementation delay was reported by month, quarter, and year.
Results:
Delaying PCV20 implementation in French children was estimated to result in preventable 15,356 disease cases and 1,489 deaths over two years, with cost of €117.4 million, versus the continuous use of PCV15. PCV20 versus PCV13 results were slightly reduced but followed a similar trend.
Conclusions:
Rapid implementation of PCV20 is estimated to prevent thousands of cases and deaths over two years compared to the continuous PCV15 or PCV13 use, reducing significant negative impact to public health outcomes and waste of health care resources.
